KRRO earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -1.00. Updated 2026-07-23.
Korro Bio (KRRO) Research Hub
Korro Bio (KRRO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 13.81 USD (+6.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.00, market cap 0.12B. This hub links to the full technical, earnings and options research available for KRRO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 13.81 USD (+6.81%) |
| 52-week range | 9.76 USD – 15.55 USD |
| Trend regime | Range |
| 14-day RSI | 53.6 (Neutral) |
| Trailing P/E | -1.00 |
| Market cap | 0.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for KRRO
Covered Call on KRRO: how it works, illustrative setup around the real 13.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KRRO: how it works, illustrative setup around the real 13.81 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KRRO: how it works, illustrative setup around the real 13.81 USD price, max profit/loss, breakeven and when to use it. Educational.
KRRO technical analysis: range, last 13.81 USD, RSI 53.6, 52w range 9.76 USD–15.55 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KRRO in?
Korro Bio (KRRO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KRRO in an uptrend or downtrend?
As of 2026-09-11, KRRO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KRRO's trailing P/E ratio?
KRRO's trailing P/E is -1.00, with a market cap of 0.12B. See the earnings research page for full valuation detail.
When does KRRO next report earnings?
KRRO is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -1.338 USD.